News | Peripheral Artery Disease (PAD) | July 17, 2019

Annual U.S. Economic Burden of Critical Limb Ischemia Exceeds $200 Billion

New report from The Sage Group finds inpatient hospitalizations account for majority of costs

Annual U.S. Economic Burden of Critical Limb Ischemia Exceeds $200 Billion

July 17, 2019 — A new analysis published by The Sage Group LLC concludes that the all-cause cost of critical limb ischemia (CLI) exceeds $200 billion in the United States.

“CLI is an extremely expensive disease,” stated Mary L. Yost, president of The Sage Group, a research and consulting company specializing in peripheral vascular disease in the lower limbs — specifically chronic venous disease (CVD), peripheral artery disease (PAD), CLI, IC, diabetic foot ulcers (DFU) and the costs and consequences of amputation. “Inpatient hospitalizations account for the majority of costs with Medicare paying 73 percent of the bill.”

“Treatment with major amputation is one well-known factor that increases CLI costs,” observed Yost. “Amazingly, revascularization is underutilized in CLI patients. Between 25-33 percent of CLI patients are treated with primary amputation, which is more expensive than revascularization. The higher hospital costs of major amputation reflect more frequent and expensive complications, increased in-hospital mortality and more revision procedures,” she stated.

“However, there are many other factors that drive up CLI costs,” she continued. “Most of these, including amputation, are either modifiable or preventable.”

“Costs increase with disease severity,” Yost stated, “Rutherford 6 patients with gangrene incur higher costs than Rutherford 4 and 5 with rest pain and ulcers respectively. CLI treatment costs more than intermittent claudication (IC).”

“CLI-specific treatments are not the only factor increasing spending — cardiovascular events, such as heart attacks and strokes and related hospitalizations, add significantly to the economic burden,” Yost explained. “So does diabetes and diabetic hospitalizations.”

“Despite a high prevalence of cardiovascular disease and diabetes, cardiovascular risk factors and diabetes are suboptimally managed in CLI patients. This increases morbidity and mortality as well as costs, “ she continued.

“The tragedy is that earlier diagnosis of CLI and appropriate treatment, could save lives and limbs, as well as a tremendous amount of money,” concluded Yost.

CLI, or end-stage peripheral artery disease (PAD), is characterized by rest pain, ulcers and gangrene.

Read more about the report here.

For more information: www.thesagegroup.us


Related Content

News | Peripheral Artery Disease (PAD)

March 20, 2024 — Biotronik has been granted Breakthrough Device Designation (BDD) from the US Food and Drug ...

Home March 20, 2024
Home
News | Peripheral Artery Disease (PAD)

February 12, 2024 — Sensome, a company pioneering the connected medical device revolution with the world’s smallest ...

Home February 12, 2024
Home
News | Peripheral Artery Disease (PAD)

November 10, 2023 —Getinge announced commercial availability of the iCast covered stent system in the United States for ...

Home November 10, 2023
Home
News | Peripheral Artery Disease (PAD)

October 24, 2023 — Four years ago, following a publication based on the limited data available, the U.S. Food and Drug ...

Home October 24, 2023
Home
News | Peripheral Artery Disease (PAD)

September 14, 2023 — LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of ...

Home September 14, 2023
Home
News | Peripheral Artery Disease (PAD)

July 11, 2023 — The U.S. Food and Drug Administration (FDA) is informing healthcare providers about updated information ...

Home July 11, 2023
Home
News | Peripheral Artery Disease (PAD)

June 21, 2023 — A new science report issued by the American Heart Association (AHA) emphasizes the importance of ...

Home June 21, 2023
Home
News | Peripheral Artery Disease (PAD)

June 16, 2023 — Endologix LLC, a privately held, global medical device company, dedicated to providing disruptive ...

Home June 16, 2023
Home
News | Peripheral Artery Disease (PAD)

June 15, 2023 — Endologix LLC, a privately held, global medical device company dedicated to providing disruptive ...

Home June 15, 2023
Home
News | Peripheral Artery Disease (PAD)

March 8, 2023 — Treatments for peripheral artery disease (PAD) were largely developed in men and are less effective in ...

Home March 08, 2023
Home
Subscribe Now